WO2022249060 - TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN)
National phase entry:
Publication Number
WO/2022/249060
Publication Date
01.12.2022
International Application No.
PCT/IB2022/054850
International Filing Date
24.05.2022
Title **
[English]
TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN)
[French]
ANALOGUES DE TRIAZOLO-PYRIMIDINE POUR LE TRAITEMENT DE MALADIES LIÉES À L'INHIBITION DE L'HÉLICASE RECQ DU SYNDROME DE WERNER (WRN)
Applicants **
NOVARTIS AG
Inventors
BORDAS, Vincent
BRUN, Jvan
DECKER, Andrea
FUREGATI, Markus
GOGNIAT, Geoffrey
GONG, Wanben
HAMON, Jacques
HINRICHS, Juergen Hans-Hermann
HOLZER, Philipp
LIMAM, Fatma
MOEBITZ, Henrik
NOCITO, Sandro
PLATTNER, Simone
SCHMIEDEBERG, Niko
SCHOEPFER, Joseph
SOTO, Jessica
STRANG, Ross
YAO, Shuping
YU, Huangchao
ZECRI, Frédéric
ZHANG, Sisi
Priority Data
PCT/CN2021/096104
26.05.2021
CN
PCT/CN2022/085537
07.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 10751 | |
| EPO | Filing, Examination, Granting | 65996 | |
| Japan | Filing, Examination, Granting | 3789 | |
| South Korea | Filing, Examination, Granting | 5317 | |
| USA | Filing, Examination, Granting | 23140 |
Total:
108,993
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.[French]
, y, R, M, W, L, V, T, Y, J, K et A sont tels que décrits dans la description, des utilisations thérapeutiques desdits composés, des utilisations desdits composés en tant que produits chimiques de recherche, une composition pharmaceutique et des combinaisons comprenant lesdits composés, et des procédés de fabrication des composés de l'invention.